An Open-label, Multi-center Controlled Clinical Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (AHUS)

Trial Profile

An Open-label, Multi-center Controlled Clinical Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (AHUS)

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Haemolytic uraemic syndrome
  • Focus Therapeutic Use
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 05 May 2014 The US FDA has approved Alexion Pharmaceuticals' supplemental Biologics License Application (sBLA) providing regular approval for eculizumab; regular approval includes data from this study.
    • 26 Mar 2014 According to European Clinical Trials Database record, status changed from active, no longer recruiting to completed.
    • 25 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top